Phase II stroke data presented at AHA conference

Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018

26 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that positive long-term data from the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability was accepted for a podium presentation given yesterday at the American Heart Association International Stroke Conference 2018 (“ISC 2018”),  taking place this week in Los Angeles.

Read more…

To view the presentation please click here.

ReNeuron Share Capital Reorganisation RNS

23 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced on 5 January 2018 details of a proposed of the existing ordinary share capital of the Company. The Board is pleased to announce that at today’s General Meeting of the Company, Shareholders approved all of the Resolutions set out in the Circular.

Read more …

 

ReNeuron – Share Capital Reorganisation RNS – ALLOTMENT

11 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today makes the following announcement in connection with the proposed Share Capital Reorganisation of the existing ordinary share capital of the Company announced on 5 January 2018

Read more…

 

Proposed Share Capital Reorganisation and Notice of General Meeting

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a proposed Share Capital Reorganisation of the existing ordinary share capital of the Company.

Read more…

To view the circular please click here.

Interim Results for the six months ended 30 September 2017

14 December 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2017.

Read more…

To view the Interim Results Presentation slide deck please click here.

To log on to view the webcast of the analyst presentation please click here.

Stroke clinical trial regulatory approval in US

FDA approves ReNeuron’s IND application to commence a Phase IIb clinical trial in the US in stroke disability

14 December 2017: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the FDA has given regulatory approval for the Company to commence a Phase IIb clinical study in the US with its CTX cell therapy candidate for stroke disability.

Read more…

ReNeuron opens US office

8 December 2017: ReNeuron Group plc (AIM: RENE) , a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA.

Read more…

 

Notification of Interim Results

13 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2017 on Thursday 14 December 2017.

Read more…

Retinal disease clinical trial moves into Phase II

Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data

8 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s ongoing Phase I/II clinical trial of its hRPC cell therapy candidate for the blindness-causing disease, retinitis pigmentosa (“RP”).

Read more…

Positive stroke clinical data & regulatory update

Long term data from Phase II stroke clinical trial confirm positive results seen after three months.

Results indicate that CTX cell therapy has potential to improve long term outcomes in disability, dependence and motor function in disabled stroke patients.

31 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability and, in addition, an update regarding its global clinical and regulatory development strategy for the stroke programme.

Read more…